If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged 12 ...

The medication, gepotidacin, targets E. coli bacteria, which is responsible for the most common types of infections, called uncomplicated UTIs, that affect women. Advertisement Advertisement Called ...

The FDA has approved the drug for use in women and girls over the age of 12 who suffer from uncomplicated urinary tract ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

The drug, known in development as gepotidacin, will be marketed under the brand name Blujepa. GSK said it plans to launch the new product in the second half of this year. Uncomplicated UTIs are ...

London: GSK plc has announced that the Company has received US Food and Drug Administration (FDA) approval for Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients ...